Intravenous immunoglobulin for immune deficiency
Part of Genetic & congenital, Immune system & allergy clinical trials.
This study tests an intravenous immunoglobulin (IVIG) treatment, which is a way of giving you antibodies to help fight infections. It aims to see if this treatment is safe and effective for people with certain immune deficiencies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 2 and 65 years old.
- You need a confirmed diagnosis of primary immunodeficiency, specifically common variable immunodeficiency (CVID) or X-linked agammaglobulinemia (XLA), with low antibody levels (IgG below 500 mg/dL).
- Either you've never had immunoglobulin therapy, or you've been receiving IVIG infusions every 3 or 4 weeks for at least 6 months.
- Your blood counts and liver/kidney function tests must be within certain limits (e.g., white blood cells ≥3.5 x 10^9/L, platelets ≥100 x 10^9/L).
- If you're a woman who could become pregnant, you must agree to use effective birth control during the study.
- You cannot be pregnant, breastfeeding, or planning pregnancy within 18 months of joining.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is a safety check for people with primary immunodeficiency who are already using a specific immune globulin treatment given under the skin. It looks at medical records to see if any side effects occurred.
This study tests whether a new antibody treatment called TAK-664 is safe and works for people with primary immunodeficiency who have never had antibody replacement before. It compares the new treatment to a standard approach, with the goal of helping prevent infections and improve quality of life.
This trial tests a new immunoglobulin treatment (V-Immune) for people with primary IgG deficiency who are already on IVIG therapy. It aims to see if this new therapy can effectively replace their current treatment.
This study looks at how well immunoglobulin replacement therapy works in people with low antibody levels and how it affects the immune system. It aims to help improve treatment for primary antibody immunodeficiencies.
This study tests an intravenous (IV) immunoglobulin treatment called IVIG Boya for people with certain primary immune deficiencies. It looks at how safe it is, how well it works, and how the body processes it, which may help improve immune function and reduce infections.
This study looks at whether a different dose of IVIg (antibody treatment through the vein) or adding antibiotics can help prevent infections in people with low antibody levels. It's for patients already on steady IVIg who cannot safely stop it.
Hear when a new Primary Immunodeficiency Diseases (PID) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.